Stina Therese Sollid1, Moira Y S Hutchinson2, Ole M Fuskevåg3, Yngve Figenschau4, Ragnar M Joakimsen5, Henrik Schirmer6, Inger Njølstad7, Johan Svartberg5, Elena Kamycheva8, Rolf Jorde5. 1. Tromsø Endocrine Research Group, The University of Tromsø - The Arctic University of Norway, Tromsø, NorwayDivision of Internal Medicine, University Hospital of North Norway, Tromsø, Norway stina.therese.sollid@unn.no. 2. Tromsø Endocrine Research Group, The University of Tromsø - The Arctic University of Norway, Tromsø, NorwayDivision of Rehabilitation Services, University Hospital of North Norway, Tromsø, Norway. 3. Division of Diagnostic Services, University Hospital of North Norway, Tromsø, Norway. 4. Division of Diagnostic Services, University Hospital of North Norway, Tromsø, NorwayDepartment of Medical Biology, The University of Tromsø - The Arctic University of Norway, Tromsø, Norway. 5. Tromsø Endocrine Research Group, The University of Tromsø - The Arctic University of Norway, Tromsø, NorwayDivision of Internal Medicine, University Hospital of North Norway, Tromsø, NorwayDepartment of Clinical Medicine, The University of Tromsø - The Arctic University of Norway, Tromsø, Norway. 6. Department of Clinical Medicine, The University of Tromsø - The Arctic University of Norway, Tromsø, Norway. 7. Department of Community Medicine, The University of Tromsø - The Arctic University of Norway, Tromsø, Norway. 8. Tromsø Endocrine Research Group, The University of Tromsø - The Arctic University of Norway, Tromsø, NorwayDivision of Internal Medicine, University Hospital of North Norway, Tromsø, Norway.
Abstract
OBJECTIVE: In observational studies, low serum 25-hydroxyvitamin D [25(OH)D] concentrations have been associated with insulin resistance and other risk factors for cardiovascular disease. RESEARCH DESIGN AND METHODS: We present 1-year data from an ongoing 5-year trial in 511 individuals with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) randomly assigned to 20,000 IU/week vitamin D3 or placebo. An oral glucose tolerance test was performed at baseline and after 1 year. RESULTS:Mean baseline serum 25(OH)D was 59.9 nmol/L and 61.1 nmol/L in the vitamin D and placebo groups, respectively, and increased by 45.8 nmol/L and 3.4 nmol/L, respectively. With adjustment for baseline concentrations, no differences in measures of glucose metabolism, insulin secretion or sensitivity, blood pressure, or hs-CRP were found after 1 year. There was a slight, but significant decrease in total and LDL cholesterol in the vitamin D group compared with the placebo group, but as there was also a decrease in HDL cholesterol, the change in the total/HDL cholesterol ratio did not differ significantly. Only analyzing subjects with 25(OH)D <50 nmol/L did not change the results. CONCLUSIONS: This study shows that vitamin D supplementation does not improve glycemic indices, blood pressure, or lipid status in subjects with IFG and/or IGT.
RCT Entities:
OBJECTIVE: In observational studies, low serum 25-hydroxyvitamin D [25(OH)D] concentrations have been associated with insulin resistance and other risk factors for cardiovascular disease. RESEARCH DESIGN AND METHODS: We present 1-year data from an ongoing 5-year trial in 511 individuals with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) randomly assigned to 20,000 IU/week vitamin D3 or placebo. An oral glucose tolerance test was performed at baseline and after 1 year. RESULTS: Mean baseline serum 25(OH)D was 59.9 nmol/L and 61.1 nmol/L in the vitamin D and placebo groups, respectively, and increased by 45.8 nmol/L and 3.4 nmol/L, respectively. With adjustment for baseline concentrations, no differences in measures of glucose metabolism, insulin secretion or sensitivity, blood pressure, or hs-CRP were found after 1 year. There was a slight, but significant decrease in total and LDL cholesterol in the vitamin D group compared with the placebo group, but as there was also a decrease in HDL cholesterol, the change in the total/HDL cholesterol ratio did not differ significantly. Only analyzing subjects with 25(OH)D <50 nmol/L did not change the results. CONCLUSIONS: This study shows that vitamin D supplementation does not improve glycemic indices, blood pressure, or lipid status in subjects with IFG and/or IGT.
Authors: Kumaravel Rajakumar; Charity G Moore; Arshad T Khalid; Abbe N Vallejo; Mohamed A Virji; Michael F Holick; Susan L Greenspan; Silva Arslanian; Steven E Reis Journal: Am J Clin Nutr Date: 2020-04-01 Impact factor: 7.045
Authors: Karin Ma Swart; Paul Lips; Ingeborg A Brouwer; Rolf Jorde; Martijn W Heymans; Guri Grimnes; Martin R Grübler; Martin Gaksch; Andreas Tomaschitz; Stefan Pilz; Gudny Eiriksdottir; Vilmundur Gudnason; Louise Wamberg; Lars Rejnmark; Christopher T Sempos; Ramón A Durazo-Arvizu; Kirsten G Dowling; George Hull; Zuzana Škrabáková; Mairead Kiely; Kevin D Cashman; Natasja M van Schoor Journal: Am J Clin Nutr Date: 2018-06-01 Impact factor: 7.045